CD8A and neoplasm: Recently, it was shown that treatment of DCs with LPS (a TLR-4 ligand) or Pam3 (a TLR-1/2 ligand) leads to secretion of Dexo with an increased ability to stimulate cytotoxic natural killer (NK) and CD8+ T cells and significantly affect tumor growth in vivo16, 21, 22.